Literature DB >> 18575956

Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs.

A Mori1, T Sako, P Lee, T Motoike, K Iwase, Y Kanaya, H Fukuta, H Mizutani, T Arai.   

Abstract

Intermediate insulin injections are commonly used for glycemic control in insulin dependent diabetic dogs acting as a replacement for natural insulin. Neutral Protamin Hagedorn (NPH) insulin and insulin glargine are two types of injectable insulin preparations commonly used in humans. In our study, we investigated the time-action profiles of both aforementioned insulin preparations in normal dogs in order to determine whether co-administration of NPH and glargine would be of benefit to insulin dependent diabetic dogs as it is for humans suffering from insulin dependent diabetes. Time-action profiles of NPH insulin and insulin glargine in normal dogs demonstrated a clear difference between both insulin preparations confirming that NPH insulin is an intermediate-acting preparation whereas insulin glargine is a long-lasting preparation. In addition, co-administration of NPH insulin and insulin glargine resulted in tight glycemic control as compared to NPH insulin alone in insulin dependent diabetic dogs. However, co-administration result in hypoglycemia at the dosages tested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575956     DOI: 10.1007/s11259-008-9059-5

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  9 in total

1.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

Authors:  L Heinemann; R Linkeschova; K Rave; B Hompesch; M Sedlak; T Heise
Journal:  Diabetes Care       Date:  2000-05       Impact factor: 19.112

2.  Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.

Authors:  K Rave; L Nosek; L Heinemann; A Frick; R Becker
Journal:  Diabetes Metab       Date:  2003-09       Impact factor: 6.041

Review 3.  Update on drugs used to treat endocrine diseases in small animals.

Authors:  Ellen N Behrend
Journal:  Vet Clin North Am Small Anim Pract       Date:  2006-09       Impact factor: 2.093

4.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Authors:  M Lepore; S Pampanelli; C Fanelli; F Porcellati; L Bartocci; A Di Vincenzo; C Cordoni; E Costa; P Brunetti; G B Bolli
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

5.  Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

Authors:  Paolo Rossetti; Simone Pampanelli; Carmine Fanelli; Francesca Porcellati; Emanuela Costa; Elisabetta Torlone; Luciano Scionti; Geremia B Bolli
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

6.  Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.

Authors:  Nuala P Murphy; Suzanne M Keane; Ken K Ong; Martha Ford-Adams; Julie A Edge; Carlo L Acerini; David B Dunger
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

7.  Changes in activities of enzymes related to energy metabolism in peripheral leukocytes of diabetic dogs with glycemic control by intensive insulin treatment.

Authors:  T Arai; M Nakamura; E Magori; H Fukuda; H Mizutani; E Kawakami; T Sako
Journal:  Res Vet Sci       Date:  2002-10       Impact factor: 2.534

8.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Authors:  Tim Heise; Leszek Nosek; Birgitte Biilmann Rønn; Lars Endahl; Lutz Heinemann; Christoph Kapitza; Eberhard Draeger
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

  9 in total
  6 in total

1.  Comparison of Insulins Glargine and Degludec in Diabetic Rhesus Macaques (Macaca mulatta) with CGM Devices.

Authors:  Samantha C Puglisi; Alexis L Mackiewicz; Amir Ardeshir; Laura M Garzel; Kari L Christe
Journal:  Comp Med       Date:  2021-05-25       Impact factor: 0.982

2.  Supplementing transglucosidase with a high-fiber diet for prevention of postprandial hyperglycemia in streptozotocin-induced diabetic dogs.

Authors:  Toshinori Sako; Akihiro Mori; Peter Lee; Hiroshi Goto; Hiroko Fukuta; Hitomi Oda; Kaori Saeki; Yohei Miki; Yuki Makino; Katsumi Ishioka; Hisashi Mizutani; Yuzo Kojima; Satoshi Koikeda; Toshiro Arai
Journal:  Vet Res Commun       Date:  2010-02-18       Impact factor: 2.459

3.  Serum glycated albumin: Potential use as an index of glycemic control in diabetic dogs.

Authors:  T Sako; A Mori; P Lee; T Sato; H Mizutani; T Takahashi; Y Kiyosawa; H Tazaki; T Arai
Journal:  Vet Res Commun       Date:  2008-12-03       Impact factor: 2.459

Review 4.  Insulins for the long term management of diabetes mellitus in dogs: a review.

Authors:  Robert E Shiel; Carmel T Mooney
Journal:  Canine Med Genet       Date:  2022-02-14

5.  The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period.

Authors:  Hitomi Oda; Akihiro Mori; Toshinori Sako
Journal:  J Vet Med Sci       Date:  2020-04-20       Impact factor: 1.267

6.  Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.

Authors:  Hitomi Oda; Akihiro Mori; Satoko Ishii; Saori Shono; Eri Onozawa; Toshinori Sako
Journal:  J Vet Med Sci       Date:  2018-10-11       Impact factor: 1.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.